Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ci 1033
2. Ci-1033
3. Ci1033
1. 267243-28-7
2. Ci-1033
3. Pd-183805
4. Canertinib (ci-1033)
5. Canertinib Free Base
6. N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
7. N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide
8. C78w1k5asf
9. Chembl31965
10. N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide
11. Chebi:61399
12. 267243-28-7 (free Base)
13. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide
14. Ncgc00182713-01
15. Pd183805
16. Canertinib [inn]
17. Canertinib [inn:ban]
18. Sn-26606
19. Ci-1033(canertinib)
20. Ci1033
21. Unii-c78w1k5asf
22. Canetinib
23. Canertinib [mi]
24. Caneritinib; Ci-1033
25. Canertinib - Ci-1033
26. Ci-1033 (canertinib)
27. Canertinib [who-dd]
28. Dsstox_cid_28869
29. Dsstox_rid_83138
30. Dsstox_gsid_48943
31. Schembl54837
32. Mls004774146
33. Pd 183805 Dihydrochloride
34. Bdbm4779
35. Cid_156414
36. Gtpl5675
37. Dtxsid8048943
38. Ex-a078
39. Bcpp000301
40. Hms3244m17
41. Hms3244m18
42. Hms3244n17
43. Bcp01790
44. Tox21_113361
45. Nsc780019
46. Nsc801011
47. S1019
48. Zinc27439698
49. Akos005145818
50. Bcp9000481
51. Bcp9000482
52. Bcp9000525
53. Ccg-269588
54. Cs-0121
55. Db05424
56. Nsc-780019
57. Nsc-801011
58. Sb16594
59. N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide
60. N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide
61. Ncgc00182713-02
62. Ncgc00182713-18
63. As-56189
64. Hy-10367
65. Smr003500789
66. Pd0183805
67. Cas-267243-28-7
68. Ft-0654215
69. Ec-000.2258
70. A25038
71. 499c452
72. Q5032274
73. 2-propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-
74. N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide
75. N-[4-(3-chloro-4-fluoro-phenyl-amino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide
Molecular Weight | 485.9 g/mol |
---|---|
Molecular Formula | C24H25ClFN5O3 |
XLogP3 | 3.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 9 |
Exact Mass | 485.1629955 g/mol |
Monoisotopic Mass | 485.1629955 g/mol |
Topological Polar Surface Area | 88.6 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 671 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in breast cancer and lung cancer.
CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.
ABOUT THIS PAGE
A Canertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Canertinib, including repackagers and relabelers. The FDA regulates Canertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Canertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Canertinib supplier is an individual or a company that provides Canertinib active pharmaceutical ingredient (API) or Canertinib finished formulations upon request. The Canertinib suppliers may include Canertinib API manufacturers, exporters, distributors and traders.
Canertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Canertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Canertinib GMP manufacturer or Canertinib GMP API supplier for your needs.
A Canertinib CoA (Certificate of Analysis) is a formal document that attests to Canertinib's compliance with Canertinib specifications and serves as a tool for batch-level quality control.
Canertinib CoA mostly includes findings from lab analyses of a specific batch. For each Canertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Canertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Canertinib EP), Canertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Canertinib USP).
LOOKING FOR A SUPPLIER?